Company research / BTCY

Biotricity Inc. (BTCY)

SEC name BIOTRICITY INC. · CIK 0001630113 · OTC · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated NV
  • Fiscal year ends around Mar 31

For the year ended 2026-03-31, Biotricity Inc. reported revenue of $16.00M. Revenue grew 16.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $16.40M.

Key ratios (year ended 2026-03-31)

80.9%
Gross margin
10.6%
Operating margin
-15.0%
Net margin
16.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-28

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-6, first reflected in a filing dated 2023-11-14. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Revenue$16.40M$16.00M$13.79M$12.06M$9.64M$7.65M$3.38M$1.42M$398.2Kn/an/a
Cost of Revenue$3.04M$3.05M$3.23M$3.71M$4.20M$3.08M$2.11M$932.0K$338.3Kn/an/a
Gross Profit$13.36M$12.95M$10.56M$8.36M$5.44M$4.57M$1.27M$485.8K$59.9Kn/an/a
R&D Expense$2.74M$2.76M$2.16M$2.57M$3.23M$2.74M$2.06M$1.36M$1.31M$1.76M$1.14M
Operating Income$1.57M$1.69M-$2.45M-$8.83M-$15.41M-$16.74Mn/an/an/an/an/a
Depreciation & Amortizationn/an/an/an/an/an/a$2.48M$92.4Kn/an/an/a
Net Income-$2.69M-$2.40M-$8.42M-$14.09M-$18.66M-$29.13M-$15.49M-$11.07M-$8.59M-$8.62M-$7.81M
EPS (Diluted)n/a-$0.12-$0.56-$1.66-$2.26n/an/an/an/an/an/a
Total Assets$6.02M$6.45M$5.64M$5.94M$6.51M$16.68M$4.44M$2.00M$490.7K$929.4K$473.5K
Total Liabilities$39.72M$39.41M$35.66M$35.92M$26.36M$18.82M$11.27M$5.00M$2.27M$756.2K$4.86M
Shareholders' Equity-$35.41M-$34.68M-$32.01M-$31.47M-$19.85M-$2.14M-$6.83M-$3.00M-$1.78M$173.2K-$4.38M
Cash & Equivalents$466.5K$149.8K$365.1K$786.1K$570.5K$12.07M$2.20M$949.8K$63.6K$843.6K$424.9K
Operating Cash Flow$161.7K-$719.0K-$2.38M-$6.69M-$13.55M-$15.16M-$11.08M-$7.86M-$5.22M-$4.87M-$3.75M
Capital Expendituresn/an/an/an/an/a$29.8Kn/an/an/an/an/a
Free Cash Flown/an/an/an/an/a-$15.19Mn/an/an/an/an/a
Dividends Paidn/an/an/an/an/an/a$603.0K$180.0Kn/an/an/a
Shares Outstanding20.07M28.60M26.08M9.35M8.51M49.81M36.12M32.59M31.05M23.71M18.08M
Weighted Average Diluted Sharesn/a27.30M21.52M8.99M8.66Mn/an/an/an/an/an/a
EPS (Basic)n/a-$0.12-$0.56-$1.66-$2.26-$0.67-$0.44n/an/an/an/a